BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
53.40
-0.42 (-0.78%)
At close: Dec 5, 2025, 4:00 PM EST
53.02
-0.38 (-0.71%)
After-hours: Dec 5, 2025, 5:20 PM EST
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 19 professional analysts, the 12-month price target for BioMarin Pharmaceutical stock ranges from a low of $55 to a high of $126. The average analyst price target of $88.42 forecasts a 65.58% increase in the stock price over the next year.
Price Target: $88.42 (+65.58%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 5 | 5 |
| Buy | 11 | 11 | 11 | 9 | 9 | 8 |
| Hold | 6 | 6 | 7 | 7 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 24 | 22 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $82 → $60 | Buy → Hold | Downgrades | $82 → $60 | +12.36% | Dec 3, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $73 → $61 | Strong Buy → Hold | Downgrades | $73 → $61 | +14.23% | Nov 6, 2025 |
| Bernstein | Bernstein | Buy Maintains $95 → $88 | Buy | Maintains | $95 → $88 | +64.79% | Nov 3, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $90 → $80 | Strong Buy | Maintains | $90 → $80 | +49.81% | Oct 28, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $90 → $70 | Buy | Maintains | $90 → $70 | +31.09% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
3.24B
from 2.85B
Increased by 13.39%
Revenue Next Year
3.48B
from 3.24B
Increased by 7.57%
EPS This Year
2.96
from 2.21
Increased by 34.02%
EPS Next Year
4.62
from 2.96
Increased by 56.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.4B | 3.8B | ||||
| Avg | 3.2B | 3.5B | ||||
| Low | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 17.7% | 18.0% | ||||
| Avg | 13.4% | 7.6% | ||||
| Low | 8.1% | -2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.89 | 5.95 | ||||
| Avg | 2.96 | 4.62 | ||||
| Low | 2.23 | 2.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 76.0% | 101.3% | ||||
| Avg | 34.0% | 56.3% | ||||
| Low | 1.2% | -8.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.